Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis

/PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored...

Related Keywords

California ,United States ,Alabama ,Hyderabad ,Andhra Pradesh ,India ,San Francisco ,America ,Dan Budwick ,Zelmac Chiesa ,Vivian Wu ,Jonathan Zalevsky ,Eli Lilly ,Investment Community Meeting ,Eli Lilly Company ,Exchange Commission On ,Nektar Therapeutics ,College Of Rheumatology Meeting ,Research Development ,Lilly Sponsored Phase ,Investment Community ,Eczema Area ,Severity Index ,Senior Vice President ,Chief Research ,Development Officer ,Annual College ,Quarterly Report ,Exchange Commission ,America Study ,Investigative Dermatology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,